VIPR1 and immune system disorder: Notably, treatment of wild type mice with 10 days of daily subcutaneous injections of the ANT008 or ANT308 VIP-R antagonists was not associated with histopathological evidence of autoimmunity, consistent with the absence of auto-immune disease in VIP knockout mice55 and no evident effect on behavior56,57.